ArticleLa Tunisie medicale2024
Predictive factors for severe epistaxis in a tertiary center of Tunisia.
Article in La Tunisie medicale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpistaxis is a prevalent clinical condition that can be associated with significant morbidity and places a considerable burden on the healthcare system.
aimTo ascertain the prevalence of epistaxis in our center and to identify the predictive factors of severity.
methodsThis is a retrospective cross-sectional analytical study of patients who presented to and/or were admitted for epistaxis at our department of Ear, Nose and Throat (ENT) during the period from January 2015 to December 2022.
resultsA total of 720 patients were included out of a total of 100,378 consultations, resulting in a prevalence of 0.7%. The mean age of the patients was 51.6 years (±18,73 Standard Deviation (SD)) and the sex ratio H/F was 1.43. The majority (87.9%) of cases were benign and treated on an outpatient basis, while 12.1% of patients presented with severe epistaxis and required hospitalization. The median duration of hospitalization was 5 days. The outcome was favourable in 99.4% of cases. Nevertheless, two cases of death due to severe epistaxis complicated by hemorrhagic shock were observed. A multivariate analysis identified several independent factors associated with severe epistaxis. These included male gender, recurrent epistaxis, a history of hematological disorders, the use of anticoagulant therapy, and an increased International Normalized Ratio (INR) level.
conclusionThese results have made a significant contribution to our understanding of the severity factors associated with epistaxis, enabling a more targeted and personalized approach to prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.